Pınar MUTLU, Nilüfer AYLANÇ, N.arzu MİRİCİ, Merve İLÇİN GÜVEN

KRONİK OBSTRÜKTİF AKCİĞER HASTALIĞINDA FENOTİPLERE GÖRE KAN BİYOBELİRTEÇLERİNİN KARŞILAŞTIRILMASI

Amaç: Kronik obstrüktif akciğer hastalığı (KOAH)'nda hava yolu inflamasyonu, biyobelirteçler kullanılarak ölçülebilir. Bu çalışma, sistemik inflamasyonun biyobelirteçlerini kullanarak KOAH'ın heterojenliğini araştırmak için yapılmıştır.Gereç ve Yöntem: 19 KOAH'lı hastanın toraks bilgisayar tomografisi amfizem baskın ve kronik bronşit baskın olmasına göre değerlendirildi ve kan biyobelirteçleriyle karşılaştırıldı.Bulgular: Çalışma grubunun yaş ortalaması 72,1±8,0 yıldı. KOAH fenotipiyle kan biyobelirteçleri arasında bir fark saptanmazken, amfizem baskın ile kronik bronşit arasında, toraks anteroposterior (AP) ve transvers çap açısından istatistiksel olarak anlamlı fark saptanmıştır. AP çap/transvers çap oranı ile TNF-alfa arasında pozitif yönlü güçlü istatistiksel olarak anlamlı korelasyon saptandı. Sonuç: Yaygın kronik bronşitli hastalar ile yaygın pulmoner amfizemi olan hastalar arasında inflamatuar biyobelirteçler açısından anlamlı fark bulunmaması, bu iki klinik ve fonksiyonel fenotipin benzer inflamatuar bir paterne sahip olabileceğini düşündürmüştür. Sonuç olarak, KOAH'ın fenotipik ayrımı ya da tedaviye yanıtın değerlendirilmesi için biyobelirteçlerin kullanımına büyük bir ilgi vardır. Sonuçlarımızın, daha büyük klinik çalışmaların planlanmasında fayda sağlayacağını düşünüyoruz.

Anahtar Kelimeler:

KOAH, Fenotipler, Biyomarkırlar

COMPARISON OF BLOOD BIOMARKERS WITH PHENOTYPES IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Purpose: Airway inflammation in chronic obstructive pulmonary disease (COPD) can be measured using biomarkers. This study was conducted to investigate the heterogeneity of COPD using biomarkers of systemic inflammation.Materials and Methods: Thirty-six patients with COPD had thoracic computer tomography assessed as predominantly emphysematous and chronic bronchitis predominance and compared with blood biomarkers.Results: The mean age of the study group was 72,1±8,0 years. There was a statistically significant difference between AP and transverse diameter between emphysema predominant and chronic bronchitis. There was a positive statistically significant correlation between thorax anteroposterior (AP) diameter and transverse diameter ratio and TNF-alpha, while no difference was found between COPD phenotype and blood biomarkers. Conclusion: The absence of a significant difference in inflammatory biomarkers between patients with diffuse chronic bronchitis and those with diffuse pulmonary emphysema suggests that these two clinical and functional phenotypes may have a similar inflammatory pattern. In conclusion, there is great interest in the use of biomarkers for assessing phenotypic discrimination or response to COPD. We think that our results will be beneficial in planning larger clinical trials.

Keywords:

COPD, Phenotypes, Biomarkers,

PDF

___

Referans 1) Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden ofCOPD: systematic review and meta-analysis.Eur Respir J 2006; 28: 523–532.
Referans 2) American Thoracic Society. Standards for the diagnosis and care of patients withchronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152:s77–s121.
Referans 3 )Chung KF, Adcock IM. Multifaceted mechanisms in COPD: inflammation, immunity,and tissue repair and destruction. Eur Respir J 2008; 31: 1334–1356.
Referans 4) Burrows B, Fletcher CM, Heard BE, Jones NL, Wootliff JS. The emphysematous and bronchial types of chronic airways obstruction. A clinicopathological study of patients in Londonand Chicago. Lancet 1966;1:830e5.
Referans 5) Snoeck-Stroband JB, Lapperre TS, Gosman MM, Boezen HM,Timens W, ten Hacken NH, et al Corticosteroids in Obstructive Lung Disease (GLUCOLD) Study Group. Chronic bronchitis sub-phenotype within COPD: inflammation in sputum and biopsies.Eur Respir J 2008;31:70e7.
Referans 6) Rogers DF. The role of airway secretions in COPD: pathophysiology,epidemiology and pharmacotherapeutic options. COPD 2005;2:341e53.
Referans 7) Miravitlles M. Cough and sputum production as risk factors for poor outcomes in patients with COPD. Respir Med 2011;105:1118e28.
Referans 8) Kim V, Han MK, Vance GB, Make BJ, Newell JD, Hokanson JE. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene study. Chest 2011;140:626e33.
Referans 9) Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, et alEvaluation of COPD longitudinally to identify predictive surrogate endpoints (ECLIPSE) investigators. Characterisationof COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010;10(11):122.
Referans 10) Boschetto P, Miniati M, Miotto D, Braccioni F, De Rosa E, Bononi I, Papi A, Saetta M, FabbriLM, Mapp CE. Predominant emphysema phenotype in chronic obstructive pulmonarydisease patients. Eur Respir J 2003; 21: 450–454.
Referans 11) Boschetto P, Quintavalle S, Zeni E, Leprotti S, Potena A, Ballerin L, Papi A, Palladini G,Luisetti M, Annovazzi L, Iadarola P, De RosaE, Fabbri LM, Mapp CE. Association betweenmarkers of emphysema and more severe chronic obstructive pulmonary disease.Thorax 2006; 61: 1037–1042.
Referans 12) Balbi B, Majori M, Bertacco S.Inhaled corticosteroids in stable COPD patients. Do they have effects on cells and molecular mediators of airway inflammation? Chest 2000;117:1633–7.Referans 13) Llewellyn-Jones CG, Harris TA, Stockley RA. Effects of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema. Am J Crit Care Med 1996;153:616–21.
Referans 14) Miniati M, Filippi E, Falaschi F, Carrozzi L, Milne EN, Sostman HD, Pistolesi M. Radiologicevaluation of emphysema in patients with chronic obstructive pulmonary disease.Chest radiography versus high-resolution computed tomography. Am J Respir CritCare Med 1995; 151: 1359–1367.
Referans 15) Milne ENC, Pistolesi M. Detecting and quantifying chronic bronchitis and emphysema;in Milne ENC, Pistolesi M (eds).Reading the Chest Radiograph. A Physiologic Approach.St Louis, Mosby, 1993, pp 267–310.
Referans 16) Reid MB, Li YP. Tumor necrosis factor-alpha and muscle wasting:a cellular perspective. Respir Res 2001, 2(5):269-72.